Could Athenex Inc (NASDAQ:ATNX) Skyrocket? The Stock Had Too Little Sellers

November 10, 2018 - By Vivian Park

The stock of Athenex Inc (NASDAQ:ATNX) registered a decrease of 5.9% in short interest. ATNX’s total short interest was 3.57M shares in November as published by FINRA. Its down 5.9% from 3.80M shares, reported previously. With 219,200 shares average volume, it will take short sellers 16 days to cover their ATNX’s short positions. The short interest to Athenex Inc’s float is 10.2%.

The stock decreased 4.05% or $0.51 during the last trading session, reaching $12.09. About 178,197 shares traded. Athenex, Inc. (NASDAQ:ATNX) has declined 4.41% since November 10, 2017 and is downtrending. It has underperformed by 20.03% the S&P500.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. The company has market cap of $807.67 million. The Company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. It currently has negative earnings. The firm also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas.

More important recent Athenex, Inc. (NASDAQ:ATNX) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on October 25, 2018, also Seekingalpha.com published article titled: “Athenex reports positive data on T-cell therapy”, Globenewswire.com published: “Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress” on October 16, 2018. More interesting news about Athenex, Inc. (NASDAQ:ATNX) was released by: Streetinsider.com and their article: “Athenex (ATNX) Announces FDA Allowance of IND Application of Eribulin ORA to Begin Clinical Trials” with publication date: October 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>